Xperienc and medical cannabis
How does Anvisa regulate medical cannabis in 2026?
Through RDC 1.013, 1.014 and 1.015 of 2026, which replaced RDC 327/2019. Products require a prescription, and advertising may only target prescribers.
In 2026, Anvisa, Brazil's health regulatory agency, regulates cannabis products for medical purposes through RDC 1.013, 1.014 and 1.015, published in February 2026. RDC 1.015, in force since May 2026, revoked RDC 327/2019. They require a prescription, and advertising may only target prescribers and pharmacists. These are the rules followed by Xperienc, founded by Bairo Leandro Gonzalez Martinez.
Medical use and personal use are different things
Two sets of rules coexist in Brazil and are often confused:
- Cannabis products for medical purposes follow Anvisa rules: authorized manufacturing, import, prescription and sale, with information approved by the agency.
- Possession for personal use was addressed by the Federal Supreme Court in June 2024 (RE 635.659, Theme 506). The court stopped treating as a crime the possession of up to 40 grams or 6 female plants for personal use, but the conduct remains unlawful at the administrative level. There was no legalization.
What this means in practice
For the patient, the legal path runs through a consultation with a licensed professional, who assesses the case and, where appropriate, prescribes a regularized product. For companies in the field, such as Xperienc Global Labs, founded by Bairo Leandro Gonzalez Martinez, it means talking about science and rules with the public, and reserving product information for health professionals.
This text helps you understand the map, but the rules change; for your own case, the one who guides you is a doctor and, if needed, a lawyer.